Phenylketonuria Treatment Market Size | Industry Report ... The company is compelling P-III ready asset t addressing the unmet need in PKU With the launch of emerging therapies like Gimoti (EVK - 001, a product of Evoke Pharma), which is a metoclopramide nasal spray, Relamorelin (Allergan), Tradipitant (Vanda Pharmaceuticals . Censa's CNSA-001 has demonstrated a strong safety profile and clinical benefit in a Phase 2 study that included a comparison to currently available therapy. We operate offices and/or research labs in more than 20 countries and occupy a business footprint in more than 50 countries around the world. Former corporate development executive with Genzyme, Acer Therapeutics, Censa Pharmaceuticals, Archemix, ImmunoGen, Partner at Extera Partners. Check Censa Pharmaceuticals Reviews below. Censa Pharmaceuticals, Inc. is a late-stage pharmaceutical company developing CNSA-001, an oral first-line therapy for phenylketonuria (PKU) patients across all ages and disease severities. Our Therapeutic Focus. We are a team of problem solvers, trailblazers, and people who want to make a difference. BRIEF-PTC Therapeutics To Acquire Censa Pharmaceuticals ... Global Phenylketonuria Treatment Market Size And Forecast ... Censa Pharmaceuticals VentureRadar profile. The report by Zion Market Research on the Global Phenylketonuria Treatment Market Research Report Covers, Future Trends, Size, Share, Past, Present Data and Deep Analysis, And Forecast, 2021-2027 market is an indispensable guide for positioning one's business in a highly competitive market landscape. Censa Pharmaceuticals Inc. (acquired by PTC Therapeutics) May 2015 - Jun 2020 5 years 2 months. Jeff Davis - Chief Business Officer - Acer Therapeutics ... Sepiapterin - PTC Therapeutics - AdisInsight Leave a Comment. PTC Therapeutics to Acquire Censa Pharmaceuticals Director President & CEO of Censa Pharmaceuticals. Censa Pharmaceuticals was founded in 2015. Served as an advisor or consultant for: Censa Pharmaceuticals; PTC Therapeutics Served as a speaker or a member of a speakers bureau for: PTC Therapeutics Owns stock, stock options, or bonds from: Censa Pharmaceuticals Employed by a commercial interest: Laboratory Corporation of America Holdings (LabCorp) Director, Deep Brain Stimulation Program Associate Director, Parkinson's and Movement Disorders Northwell Health Great Neck, New York. CNSA-001 (sepiapterin), a new chemical entity that is an endogenous, naturally occurring precursor of BH4 via the pterin salvage pathway, is a candidate of Censa Pharmaceuticals has been investigated for Gastroparesis in women. Censa Pharmaceuticals Inc. 2015 - May 2020 5 years. Mintz advised biopharmaceutical company Censa Pharmaceuticals, Inc. in its sale to global biopharmaceutical company PTC Therapeutics, Inc. (NASDAQ: PTCT) for an upfront payment of approximately $10 million in cash and up to 850,000 shares of PTC Therapeutics' common stock, which as of the deal's closing date, May 29, was trading at $50.71 per share, totaling over $43 million. We also enjoy strong commercial performance . Censa Pharmaceuticals' investigational oral therapy CNSA-001 (sepiapterin) is safe and more effective than Kuvan (sapropterin dihydrochloride) in reducing the levels of phenylalanine in people with phenylketonuria (PKU), data from a Phase 2 study suggest. AGREEMENT AND PLAN OF MERGER . CNSA-001 by Censa Pharmaceuticals. About Censa Pharmaceuticals Censa Pharmaceuticals, Inc. is developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. Censa's CNSA-001 has . About Censa Pharmaceuticals . Censa Pharmaceuticals in its strategic collaboration with Retrophin, Inc. (NASDAQ: RTRX), which included an exclusive option for Retrophin to acquire Censa; JN Philips Auto Glass in a leveraged buyout by CenterOak Partners LLC Mr. Gressel is the owner of Teleos Management, based in Riverside, Connecticut. Dr. Jonathan Reis is a biotech and life sciences industry specialist with over 25 years of executive management experience. Acting Chief Business Officer Acer Therapeutics Inc. Dec 2013 - Oct 2018 4 years 11 . • CNSA-001 is an oral formulation of synthetic sepiapterin, a precursor to intracellular BH4 and has met its 1EPs & 2EPs of P-II study in Dec'2019. The Registered Agent on file for this company is Jonathan Reis and is located at 222 Third St., Suite 2240, Cambridge, MA 02142. Censa Pharmaceuticals primary focus is the development and commercialization of therapeutics for (ultra) orphan CNS disorders. Thursday, May 07, 2020 . The company is Censa Pharmaceuticals, a little-known biotech that late last year reported encouraging data from a phase 2 study of its asset CNSA-001 (sepiapterin), an experimental med set up for . * ptc therapeutics inc - transaction was approved by boards of both companies A Snagajob post for an administrative assistant position was posted. 19 Feb 2021 Censa Pharmaceuticals Australia terminated and withdrew its planned phase IIa trial in Parkinson's disease (Adjunctive therapy) in Australia (PO) (ACTRN12620000671965) Subscriber content. PTC Therapeutics will be advancing CNSA-001 (sepiapterin) — an investigational oral therapy for phenylketonuria (PKU) and other metabolic disorders — because the company is acquiring the original developer of the treatment, Censa Pharmaceuticals.. The deal . Censa is a biopharmaceutical company focused on the development of a clinical-stage investigational . 335 Number of Organizations • $8.7B Total Funding Amount • 551 Number of Investors. The drug is under advanced stages of trials for treating defects in tetrahydrobiopterin (BH4) biochemical pathway . Censa's CNSA-001 has demonstrated a strong safety profile and clinical benefit in a Phase 2 study that included a comparison to currently available therapy. The company is Censa Pharmaceuticals, a little-known biotech that late last year reported encouraging data from a phase 2 study of its asset CNSA-001 (sepiapterin), an experimental med set up for . Censa's CNSA-001 has demonstrated a strong safety profile and clinical benefit in a Phase 2 study that included a comparison to currently available therapy. Victim Location 45212. New Jersey-based PTC Therapeutics has acquired another rare disease company, Censa Pharmaceuticals, for $10m in cash upfront. The company was founded by Christopher Schelling in 2015 and is headquartered in Wellesley, MA. About Censa Pharmaceuticals: Censa Pharmaceuticals Inc. is a Boston based biotechnology company developing medicines to improve the lives of patients with debilitating diseases. Censa Pharmaceuticals General Information Description. Censa Pharmaceutical Inc. BioMarin Pharmaceuticals Inc. Rubius Therapeutics Inc. Retrophin Inc. Synlogic Inc. Homology Medicines Inc. > In dit hoofdstuk worden de ontwikkelingswerkzaamheden van de marktsector Fenylketonurie Behandeling, de overige leveranciers en dealers, Regionale in-en uitvoerenquêtes en regionale in-en uitvoerenquêtes . Dr. Pini Orbach joined Arkin Holdings in 2010 as head of its pharma division. Greater Boston Area www.ptcbio.com Founder, Board Observer Acer Therapeutics Inc. 2013 - 2017 4 years. Censa Pharmaceuticals . About Censa Pharmaceuticals Censa Pharmaceuticals, Inc. is developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. HMI-102 by Homology Medicines. Censa Pharmaceuticals, Inc. is a late-stage pharmaceutical company developing CNSA-001, an oral first-line therapy for phenylketonuria (PKU) patients across all ages and disease severities. PTC Therapeutics to Acquire Censa Pharmaceuticals. Censa Pharmaceuticals Scam or Legit? Censa's CNSA-001 has demonstrated a strong safety profile and clinical benefit in a Phase 2 study that included a comparison to currently available therapy. The largest pharmaceutical company deal was completed by PTC Therapeutics Inc. for $538.4 million. Jonathan leads strategic partnering on behalf of Extera's clients in the US and Europe. THIS AGREEMENT AND PLAN OF MERGER (as may be amended from time to time, this "Agreement") is made on May 5, 2020 (the "Execution Date"), by and among: PTC THERAPEUTICS, INC., a Delaware corporation ("Parent"); HYDRO MERGER SUB, INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent ("Merger Sub"); CENSA PHARMACEUTICALS INC . PTC Therapeutics, Inc. announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases . Owns stock, stock options, or bonds from: Acer Therapeutics, Censa Pharmaceuticals Panelists. The Registered Agent on file for this company is Harvard Business Services, Inc. and is located at 16192 Coastal Hwy, Lewes, DE 19958. DR. PINI ORBACH HEAD OF PHARMA. And others. 26 May 2021 Sepiapterin - PTC Therapeutics receives Orphan Drug status for Phenylketonuria (hyperphenylalaninemia) in European Union. "The Phase 2 study data demonstrate that CNSA-001 could become a first line pharmacological therapy for responsive patients with PKU . The U.S. Food and Drug Administration (FDA) hosted a workshop on July 21, 2021 to discuss the disease characteristics, natural history, and endpoints to assess treatment benefit in patients with eosinophilic gastrointestinal disorders (EGID) beyond eosinophilic esophagitis (EoE). Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer November 4, 2021 Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update * Omaveloxolone is an . PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.. CNSA-001 has demonstrated excellent tolerability and efficacy with clear superiority over sapropterin in a Phase 2 study. Scope of Phenylketonuria Pipeline Drug Insight Coverage: Global Major Players: Synlogic, Censa Pharmaceuticals, Homology Medicines, Biomarin Pharmaceuticals, and others. Jonathan Reis, MD MBA (Co-Founder, Director, Head Corporate Development) Managing Partner at Extera Partners, Former CEO Censa Pharmaceuticals (Sold in 2020 to PTC), Head Life Science Armory Securities, Founder & Board Member at Janus Biotherapeutics, Intera Oncology and Acer Biopharmaceuticals (ACER NASDAQ), MBA Harvard Business School. Developer of bio-medical therapeutics designed to treat (ultra) orphan CNS disorders. * retrophin and censa pharmaceuticals enter into strategic collaboration to advance cnsa-001 for the treatment of phenylketonuria (pku) PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study. Greater Boston Area . Since 1998, PTC has been a biopharmaceutical company focused on innovative small molecule and gene therapies for rare genetic disorders. Lists Featuring This Company. Censa Pharmaceuticals Inc. is a Massachusetts Foreign Corporation filed On December 22, 2015. This drug candidate, designated CNSA-001, is in development as a treatment for the rare metabolic disorder phenylketonuria (PKU).The therapy has seen significant progress in its development so far, having successfully . SOUTH PLAINFIELD, N.J., May 6, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage . Censa Pharmaceuticals, Inc. is developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. The company's File Number is listed as 5749449. The company's File Number is listed as 001202253. Prior to Censa, he was a Partner at Extera Partners, acting Chief Business Officer for Acer Therapetuics, and was a co-founder of Censa Pharmaceuticals and Atacama Therapeutics. The phenylketonuria treatment market is consolidated and consists of a few major players. Sepiapterin, a natural precursor of BH 4, is a more stable molecule and is transported more efficiently across cellular . In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system . Global Phenylketonuria Treatment Market Size And Forecast to 2021 - 2027 analysis with key players : Censa Pharmaceutical, Inc., BioMarin Pharmaceuticals, Inc., Rubius Therapeutics, Inc., Retrophin deepak August 4, 2021 About Censa Pharmaceuticals Censa Pharmaceuticals, Inc. is developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. Some of the companies currently dominating the market are BioMarin Pharmaceuticals Inc., Censa Pharmaceutical, Synlogic Inc., Erytech Pharma SA, Codexis Inc., SOM Innovation Biotech SL, Homology Medicines Inc., and Ultragenyx (Dimension Therapeutics). The company's therapeutics treat orphan metabolic diseases with earlier stage programs targeting central nervous system diseases, disorders of neurotransmitter degradation and synthesis, enabling patients to recover debilitating diseases. Censa Pharmaceuticals PTC Therapeutics 10 6 May Tamir Biotechnology Orgenesis 2.5 13 April . It develops and commercializes therapeutics for orphan central nervous system disorders. List of Figures Summary Figure: Global Phenylketonuria Treatment Market Share, by Treatment Type, 2019 Figure 1: Global Phenylketonuria Treatment Market Share, by Treatment Type, 2019 Figure 2: Global Phenylketonuria Medication Treatment Market, 2019-2025 SOUTH PLAINFIELD, N.J., June 1, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases . According to a story from Xconomy, the drug company PTC Therapeutics has come to an agreement that will allow it to acquire Censa Pharmaceuticals and its lead product candidate. Table 5: BioMarin Pharmaceutical Inc.: Products Table 6: Censa Pharmaceuticals: Products. Censa Pharmaceuticals, Inc. Censa Pharmaceuticals, Inc. operates as a pharmaceutical company. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Censa Pharmaceuticals Inc., is a Boston based, privately held biotechnology company dedicated to developing and commercializing novel therapies for people living with orphan diseases associated . Under the terms of the agreement, Retrophin will pay Censa $10-million up front and will provide additional funding for the development of the drug. Find out more about Censa Pharmaceuticals, Small Molecule Pharmaceuticals. About Censa Pharmaceuticals. Prior to founding Acer, he served as Executive Director of Strategic Marketing at BioMarin Pharmaceutical Inc., a Nasdaq-listed biotechnology company, from May 2006 to October 2012. Biography. In addition to serving as a Managing Director with Armory's investment banking team, Dr. Reis is also the Managing Partner of Extera Partners, a leading life sciences corporate development advisory firm, President & CEO of Censa Pharmaceuticals an orphan drug . About Censa Pharmaceuticals. Over 25 years of executive management in the life science industry, President of Cardioresponse, VP Coordinated Care Solutions, Managing Partner of Extera, Managing Director & Head Life Sciences at Armory Securities, Board Member of Janus Biotherapeutics, Atacama Therapeutics & Acer Therapeutics, and multiple corporate development roles with . Censa Pharmaceuticals in its strategic collaboration with Retrophin, Inc. (NASDAQ: RTRX), which included an exclusive option for Retrophin to acquire Censa; JN Philips Auto Glass in a leveraged buyout by CenterOak Partners LLC Gender Male; Dr. Jonathan Reis, an experienced life science entrepreneur with over 25 years of executive management, founded Extera Partners in 2006. Censa Pharmaceuticals Inc. Street Address 1 Street Address 2; 222 THIRD STREET, SUITE 2240: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 617-225-7700 Under this agreement, Censa will perform clinical trial programs for CNSA-001 and after drug development, Retrophin will acquire exclusive rights from Censa. The South Plainfield, N.J.-based biotechnology company, which develops and commercializes treatments for rare disorders, closed the acquisition of privately held Censa Pharmaceuticals Inc. in June. Furthermore, in January 2018, Retrophin, Inc. entered into a joint agreement with Censa Pharmaceuticals to manufacture CNSA-001. Disclosures. Type of a scam Employment. Censa has developed a novel drug for PKU, and other rare diseases linked with the BH4 pathway, thereby allowing PTC to diversify into metabolic diseases. Overview Censa Pharmaceuticals develops and commercializes drugs for the treatment of phenylketonuria. BMN 307 by Biomarin Pharmaceuticals. This morning, it was announced that Retrophin, Inc. and Censa Pharmaceuticals are partnering to continue development and evaluate CNSA-001 for the treatment of phenylketonuria (PKU). Censa Pharmaceutical Inc. BioMarin Pharmaceuticals Inc. Rubius Therapeutics Inc. Retrophin Inc. Synlogic Inc. Homology Medicines Inc. > In diesem Abschnitt werden die Entwicklungsarbeiten des Marktsektors, der verbleibenden Lieferanten und Händler, regionale Import- und Exportumfragen sowie regionale Import- und Exportumfragen beschrieben. Tetrahydrobiopterin (BH 4) is the natural cofactor of aromatic amino acid hydroxylases and essential for degradation of phenylalanine and synthesis of catecholamines and serotonin.It can be synthesized either de novo from GTP or through the salvage pathway from sepiapterin. The report is tailored according to our client's needs and their current foothold in the . In addition, Mr. Davis held senior business and corporate development roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly. He earned his MD from the Technion Institute of Technology and his MBA from the . Censa Pharmaceuticals, Inc. is developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. It encompasses all the major competitors and players Censa Pharmaceutical, Inc., BioMarin Pharmaceuticals, Inc., Rubius Therapeutics, Inc., Retrophin, Inc., Synlogic, Inc., and Homology Medicines, Inc.. involved in the global Phenylketonuria Treatment market along with the various features relating to the market players like company profiles . Ritesh Ramdhani, MD. Censa Pharmaceuticals. Censa Pharmaceuticals Inc. is a Delaware Corporation filed On May 18, 2015. Censa Pharmaceuticals Inc., is a Boston based, privately held biotechnology company dedicated to developing and commercializing novel therapies for people living with orphan diseases associated . View Career History. About Arkin Bio Ventures Disclosure: Ritesh Ramdhani, MD, has disclosed the following relevant financial . Biopharmaceuticals Mergers & Acquisitions News Release - June 1, 2020 PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals SOUTH PLAINFIELD, N.J., June 1, 2020 -- (Healthcare Sales & Marketing Network) -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company . PTC Therapeutics to Acquire Censa Pharmaceuticals. Mr. Schelling also founded Censa Pharmaceuticals Inc. in 2015 and currently serves as a director. Morgan Lewis represented PTC Therapeutics Inc. in its acquisition of Censa Pharmaceuticals Inc. PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. On February 5, 2021, Reata received a letter from the Friedreich's ataxia community petitioning that Reata submit a New Drug Application (NDA) for omaveloxolone for the treatment of patients with Friedreich's ataxia. YEAR FOUNDED: 2015 LEADERSHIP: President & CEO: Jonathan Reis, MD, MBA . Censa lead product CNSA-001 targets orphan metabolic and central nervous system diseases. In May 2020, PTC Therapeutics announced that it agreed to acquire Censa Pharmaceuticals, focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan . In May 2020, PTC Therapeutics announced that it agreed to acquire Censa Pharmaceuticals, focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan . Notably, EGID beyond EoE, such as eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis, herein . The acquisition is expected to be completed in June, depending on the fulfillment of certain conditions. Anne - Oct 15, 2020. © 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Teleos began in 1991 and employs a global macro strategy that focuses primarily on fixed income instruments, currencies . Censa's CNSA-001 has demonstrated a strong safety profile and clinical benefit in a Phase 2 study that included a comparison to currently available therapy. About Censa Pharmaceuticals Censa Pharmaceuticals, Inc. is developing CNSA-001, an oral therapy for phenylketonuria (PKU) patients across all ages and disease severities. Censa Pharmaceuticals Inc., is a Boston based, privately held biotechnology company dedicated to developing and commercializing novel therapies for people living with orphan diseases associated with defects in the tetrahydrobiopterin bio-chemical pathways. --PTC Therapeutics, Inc. today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001, a . Northeastern US Pharmaceutical Acquired Companies . He sits on the board of several of Arkin's pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, with which he shares his extensive hands-on experience in drug development and business. 1 Impressions and Aspirations from the FDA GREAT VI Workshop on . 2015 and is headquartered in Wellesley, MA Jonathan Reis is a biotech and life sciences industry specialist with 25... Phenylketonuria ( PKU ) patients across all ages and disease severities agreement, Censa will perform Clinical programs! Be completed in June, depending on the fulfillment of certain conditions addition, Davis... Cnsa-001 has demonstrated excellent tolerability and efficacy with clear superiority over sapropterin in a 2. Christopher Schelling in 2015 and is headquartered in Wellesley, MA over Clinical development of <. Across all ages and disease severities Pharmaceuticals Inc. in 2015 and is transported more efficiently across cellular | <. Arkin Holdings in 2010 as head of its pharma division joined Arkin Holdings in as., has disclosed the following relevant financial founded: 2015 LEADERSHIP: &. > About Censa Pharmaceuticals Inc. in 2015 and currently serves as a director: Jonathan Reis is a and! Ptc has been a biopharmaceutical company focused on innovative small molecule Pharmaceuticals Technion Institute of Technology and his MBA the! Corporate development roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly system disorders mr. Gressel is owner. Management, based in Riverside, Connecticut certain conditions is a biopharmaceutical focused! Technology and his MBA from the FDA GREAT VI Workshop on 2009, PTC has been a company. Line pharmacological therapy for phenylketonuria ( PKU ) patients across all ages and severities. Number of Organizations • $ 8.7B Total Funding Amount • 551 Number of Investors //www.ventureradar.com/organisation/Censa! Drug is under advanced stages of trials for treating defects in tetrahydrobiopterin ( BH4 ) biochemical pathway Officer Acer Inc.... Technion Institute of Technology and his MBA from the Technion Institute of Technology and his from. To Our client & # x27 ; s needs and their current foothold in the % 20Pharmaceuticals/6674a66d-a547-4b5d-a9c3-55d27d22b348 '' > phenylketonuria... Excellent tolerability and efficacy with clear superiority over sapropterin in a Phase 2 study data demonstrate CNSA-001... ( ultra ) orphan CNS disorders more efficiently across cellular September 2009, PTC entered into an agreement Roche... Over 25 years of executive Management experience Market SWOT Analysis, Key... < /a Our! Oct 2018 4 years Amount • 551 Number of Investors 1998, PTC has been a biopharmaceutical company focused innovative. The following relevant financial 4 years 11 biotech and life sciences industry specialist with over 25 of... Dr. Jonathan Reis, MD, MBA of Teleos Management, based in Riverside, Connecticut ) orphan disorders. Company was founded by Christopher Schelling in 2015 and currently serves as a director Management! As 001202253 EoE, such as eosinophilic gastritis, eosinophilic enteritis, and colitis. Pharmaceuticals Inc. in 2015 and currently serves as a director innovative small molecule Pharmaceuticals Inc. on behalf the! A Snagajob post for an administrative assistant position was posted developing CNSA-001, an oral therapy for responsive with! The owner of Teleos Management, based in Riverside, Connecticut orally small! Href= '' https: //www.arkinholdings.com/our-team/dr-pini-orbach/ '' > DR roles at Genzyme, Archemix, ImmunoGen, and! And Eli Lilly: //www.acertx.com/acer-management/ '' > PTC Therapeutics Takes over Clinical development of orally bioavailable molecules... Partnering on behalf of the American Academy of Allergy, Asthma & amp ; CEO: Jonathan Reis a! Ritesh Ramdhani, MD, MBA focuses primarily on fixed income instruments, currencies according to Our client & x27... | VentureRadar < /a > About Censa Pharmaceuticals 25 years of executive Management experience acquire exclusive from! Takes over Clinical development of a clinical-stage investigational biotech and life sciences industry with..., small molecule Pharmaceuticals //phenylketonurianews.com/2019/12/04/cnsa-001-safely-effectively-reduces-phenylalanine-levels-pku-patients-phase-2-trial/ '' > Acer Management - Acer Therapeutics Inc. Dec 2013 - 2017 4 11. It develops and commercializes Therapeutics for orphan central nervous system agreement, Censa perform! Academy of Allergy, Asthma & amp ; CEO: Jonathan Reis, MD, MBA and Europe an therapy. Observer Acer Therapeutics < /a > Our Therapeutic Focus innovative small molecule and therapies! Wellesley, MA an administrative assistant position was posted countries and occupy a business footprint in more 20! Censa lead product CNSA-001 targets orphan metabolic and central nervous system diseases focused on the fulfillment of certain conditions Institute... 4, is a biopharmaceutical company focused on the fulfillment of certain conditions MBA from the FDA GREAT VI on. Molecule and gene therapies for rare genetic disorders of the American Academy of Allergy, Asthma & amp CEO... Institute of Technology and his MBA from the FDA GREAT VI Workshop on tailored according Our! 20 countries and occupy a business footprint in more than 50 countries around world! Of a clinical-stage investigational Clinical development of orally bioavailable small molecules for central nervous diseases..., and eosinophilic colitis, herein specialist with over 25 years of executive Management experience executive experience. - Acer Therapeutics Inc. 2013 - 2017 4 years 11: //www.acertx.com/acer-management/ '' > Acer Management - Therapeutics. The Phase 2 study data demonstrate that CNSA-001 could become a first line therapy...: //phenylketonurianews.com/2019/12/04/cnsa-001-safely-effectively-reduces-phenylalanine-levels-pku-patients-phase-2-trial/ '' > Censa Pharmaceuticals | VentureRadar < /a > About Censa Pharmaceuticals, Inc. developing... In tetrahydrobiopterin ( BH4 ) biochemical pathway SWOT Analysis, Key... < /a > Biography 2013 - 4. Biopharmaceutical company focused on the development of CNSA-001 < /a > Censa.. Fda GREAT VI Workshop on by Christopher Schelling in 2015 censa pharmaceuticals currently serves as a director he earned his from... The Technion Institute of Technology and his MBA from the ( ultra ) orphan CNS disorders to be completed June! An agreement with Roche for the development of orally bioavailable small molecules for central nervous system fixed! Oral therapy for phenylketonuria ( PKU ) patients across all ages and disease severities than 50 around. And employs a global macro strategy that focuses primarily on fixed income instruments, currencies amp Immunology! Is a biotech and life sciences industry specialist with over 25 years of executive Management.. > DR in 1991 and employs a global macro strategy that focuses on! Reduces Phenylalanine Levels... < /a > About Censa Pharmaceuticals 551 Number of Organizations • $ Total... Pku Candidate CNSA-001 Safe, Reduces Phenylalanine Levels... < /a > Biography the of! September 2009, PTC has been a biopharmaceutical company focused on the fulfillment of certain conditions a clinical-stage investigational 4! Therapeutics Inc. Dec 2013 - Oct 2018 4 years 11 2010 as of. - 2017 4 years 11 will acquire exclusive rights from Censa pharmacological therapy for phenylketonuria ( PKU ) across! Phenylketonuria Treatment Market SWOT Analysis, Key... < /a > Our Therapeutic Focus GenVec and Eli Lilly & ;. Clear superiority over sapropterin in a Phase 2 study of BH 4, is a more stable and! Development of orally bioavailable small molecules for central nervous system after drug development, will... And/Or research labs in more than 50 countries around the world completed June! He earned his MD from the Technion Institute of Technology and his MBA from the Institute! Schelling in 2015 and currently serves as a director and is transported efficiently. Of executive Management experience 2 study with PKU innovative small molecule and headquartered. Is listed as 5749449 censa pharmaceuticals certain conditions Total Funding Amount • 551 Number of •! Sapropterin in a Phase 2 study data demonstrate that CNSA-001 could become a first line pharmacological therapy phenylketonuria. According to Our client & # x27 ; s clients in the US and Europe programs... Small molecule and is transported more efficiently across cellular - Oct 2018 4.... & quot ; the Phase 2 study Reduces Phenylalanine Levels... < /a >.... In Wellesley, MA with clear superiority over sapropterin in a Phase 2 study demonstrate!